A detailed history of Stifel Financial Corp transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Stifel Financial Corp holds 18,167 shares of NBIX stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,167
Previous 19,118 4.97%
Holding current value
$2.28 Million
Previous $2.64 Million 5.12%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$130.86 - $143.19 $124,447 - $136,173
-951 Reduced 4.97%
18,167 $2.5 Million
Q1 2024

May 13, 2024

BUY
$130.4 - $143.74 $97,669 - $107,661
749 Added 4.08%
19,118 $2.64 Million
Q4 2023

Feb 12, 2024

SELL
$106.07 - $132.76 $45,079 - $56,422
-425 Reduced 2.26%
18,369 $2.42 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $357,464 - $445,214
3,802 Added 25.36%
18,794 $2.11 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $52,554 - $61,558
-587 Reduced 3.77%
14,992 $1.41 Million
Q1 2023

May 12, 2023

SELL
$94.11 - $123.02 $13,363 - $17,468
-142 Reduced 0.9%
15,579 $1.58 Million
Q4 2022

Feb 13, 2023

SELL
$106.72 - $127.06 $186,333 - $221,846
-1,746 Reduced 10.0%
15,721 $1.88 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $138,321 - $162,038
-1,503 Reduced 7.92%
17,467 $1.86 Million
Q2 2022

Aug 15, 2022

SELL
$75.79 - $100.07 $398,579 - $526,268
-5,259 Reduced 21.71%
18,970 $1.85 Million
Q1 2022

May 13, 2022

SELL
$72.45 - $94.81 $168,518 - $220,528
-2,326 Reduced 8.76%
24,229 $2.27 Million
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $527,203 - $703,070
-6,619 Reduced 19.95%
26,555 $2.26 Million
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $245,009 - $281,542
-2,843 Reduced 7.89%
33,174 $3.18 Million
Q2 2021

Aug 13, 2021

BUY
$89.43 - $102.27 $371,671 - $425,034
4,156 Added 13.04%
36,017 $3.51 Million
Q1 2021

May 14, 2021

BUY
$87.57 - $119.4 $78,462 - $106,982
896 Added 2.89%
31,861 $3.1 Million
Q4 2020

Feb 12, 2021

BUY
$86.91 - $108.33 $222,837 - $277,758
2,564 Added 9.03%
30,965 $2.97 Million
Q3 2020

Nov 16, 2020

BUY
$96.16 - $135.15 $490,800 - $689,805
5,104 Added 21.91%
28,401 $2.73 Million
Q2 2020

Aug 14, 2020

BUY
$85.09 - $130.36 $307,174 - $470,599
3,610 Added 18.34%
23,297 $2.84 Million
Q1 2020

May 14, 2020

SELL
$75.11 - $113.76 $218,870 - $331,496
-2,914 Reduced 12.89%
19,687 $1.72 Million
Q4 2019

Feb 13, 2020

BUY
$86.8 - $118.57 $630,168 - $860,818
7,260 Added 47.32%
22,601 $2.43 Million
Q3 2019

Nov 19, 2019

BUY
$83.82 - $101.5 $1,341 - $1,624
16 Added 0.1%
15,341 $1.4 Million
Q3 2019

Nov 13, 2019

BUY
$83.82 - $101.5 $651,868 - $789,365
7,777 Added 103.03%
15,325 $1.39 Million
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $268,371 - $339,068
3,715 Added 96.92%
7,548 $643,000
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $265,665 - $350,834
3,833 New
3,833 $344,000
Q4 2018

Feb 13, 2019

SELL
$68.32 - $124.36 $211,928 - $385,764
-3,102 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$98.88 - $125.85 $306,725 - $390,386
3,102 New
3,102 $383,000
Q4 2017

Feb 14, 2018

SELL
$58.53 - $77.59 $235,817 - $312,610
-4,029 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$47.97 - $61.28 $193,271 - $246,897
4,029
4,029 $0

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.